首页> 外文OA文献 >Phase II Trial of Reduced Intensity Busulfan / Clofarabine Conditioning with Allogeneic Hematopoietic Stem Cell Transplantation for Patients with AML, MDS, and ALL

【2h】

Phase II Trial of Reduced Intensity Busulfan / Clofarabine Conditioning with Allogeneic Hematopoietic Stem Cell Transplantation for Patients with AML, MDS, and ALL

机译：AML，MDS和ALL患者同种异体造血干细胞移植降低强度的丁硫丹/氯法拉滨调理的II期试验

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者
Chen Yi-Bin; Li Shuli; Del Rio Candice; Coughlin Erin; Ballen Karen K.; Cutler Corey S.; Dey Bimalangshu R.; Ho Vincent T.; McAfee Steven L.; Spitzer Thomas R.; Alyea Edwin P.;
展开▼
作者单位

展开▼
年度 2014
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
专利

1. Phase II Trial of Reduced-Intensity Busulfan/Clofarabine Conditioning with Allogeneic Hematopoietic Stem Cell Transplantation for Patients with Acute Myeloid Leukemia, Myelodysplastic Syndromes, and Acute Lymphoid Leukemia [J] . El-Jawahri Areej, Li Shuli, Ballen Karen K., Biology of blood and marrow transplantation: journal of the American Society for Blood and Marrow Transplantation . 2016,第1期

机译：急性髓性白血病，骨髓增生异常综合征和急性淋巴性白血病患者异体造血干细胞移植降低强度的丁硫丹/氯法拉滨调理的第二阶段试验
2. Reduced intensity vs. myeloablative conditioning with fludarabine and PK-guided busulfan in allogeneic stem cell transplantation for patients with AML/MDS [J] . Alatrash Gheath, Kidwell Kelly M., Thall Peter F., Bone marrow transplantation . 2019,第8期

机译：用氟拉马岛和PK-引导的Busulfan在异种干细胞移植中的氟胂和PK引导的血管突变，对AML / MDS的患者进行降低的强度与霉菌调节
3. Results from a clofarabine-busulfan-containing, reduced-toxicity conditioning regimen prior to allogeneic stem cell transplantation: the phase 2 prospective CLORIC trial | Haematologica [J] . Patrice Chevallier, Myriam Labopin, Gérard Socié, Haematologica . 2014,第9期

机译：异体干细胞移植前使用含氯法拉滨-白消安的毒性降低的调理方案的结果：前瞻性2期CLORIC试验|血液学
4. Intravenous Busulfan Reduces Toxicity Associated with Myeloablative Allogeneic Hematopoietic Transplantation in Patients with Myeloid Malignancies [C] . A. Shimoni, B. Bxelorai, I. Hardan, European Haematology Association . 2002

机译：静脉内的伯鲁兰减少骨髓恶性肿瘤患者患有髓鞘异产造血移植的毒性
5. Donor selection for patients undergoing allogeneic hematopoietic stem cell transplantation: Assessment of the priorities of Canadian hematopoietic stem cell transplant physicians. [D] . Tay, Jason. 2009

机译：接受同种异体造血干细胞移植的患者的供体选择：加拿大造血干细胞移植医生的优先事项评估。
6. A multicenter trial of myeloablative clofarabine and busulfan conditioning for relapsed or primary induction failure AML not in remission at the time of allogeneic hematopoietic stem cell transplantation [O] . J Magenau, P Westervelt, S Khaled, -1

机译：异基因造血干细胞移植治疗中复发或原发性诱导失败AML未缓解的清髓性氯法拉滨和环丁砜调理的多中心试验
7. Phase II Trial of Reduced-Intensity Busulfan/Clofarabine Conditioning with Allogeneic Hematopoietic Stem Cell Transplantation for Patients with Acute Myeloid Leukemia, Myelodysplastic Syndromes, and Acute Lymphoid Leukemia [O] . El-Jawahri Areej, Li Shuli, Ballen Karen K., 2016

机译：急性髓性白血病，骨髓增生异常综合征和急性淋巴性白血病患者异体造血干细胞移植降低强度的丁硫丹/氯法拉滨调理的第二阶段试验

Phase II Trial of Reduced Intensity Busulfan / Clofarabine Conditioning with Allogeneic Hematopoietic Stem Cell Transplantation for Patients with AML, MDS, and ALL

著录项

引文网络

相似文献

相关主题

期刊订阅